Lithium in Inclusion Body Myositis (IBM) (Li-IBM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00917956
Recruitment Status : Completed
First Posted : June 11, 2009
Last Update Posted : February 26, 2010
Information provided by:
Phoenix Neurological Associates, LTD

June 8, 2009
June 11, 2009
February 26, 2010
June 2008
November 2009   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00917956 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Lithium in Inclusion Body Myositis (IBM)
A Pilot Trial of Lithium in Inclusion Body Myositis (IBM)
IBM is the most common acquired muscle disease occurring over the age of 50. The underlying cause remains unknown and there is currently no effective treatment. Pathological studies have revealed abnormal collections of proteins in the muscle cells from patients with IBM. These include proteins called phosphorylated tau (p-tau). A similar process appears to occur in Alzheimer disease, with accumulations of p-tau developing in brain cells. Lithium decreases the activity of the GSK, an enzyme that has a key role in the development of p-tau. Lithium and other GSK inhibitors have been shown to decrease the accumulation of p-tau in nerve cells in animal models of Alzheimer disease. The proposed research is a pilot study to see if lithium might be an effective treatment for IBM

Trial Status Open for Enrollment

What is the Purpose of this Study? There is currently no effective treatment for IBM and its pathogenesis remains uncertain. This study is designed to test the hypothesis that treatment of patients with IBM with Lithium can improve muscle strength and reduce the markers of disease activity believed to be important in the disease pathogenesis.

Who is Eligible to Participate? Patients diagnosed with Inclusion Body Myositis above the age of 30 who have adequate muscle function for quantitative muscle testing and who have a FVC >50%. Patients who have uncontrolled diabetes, renal insufficiency, congestive heart failure, cancer, hypothyroidism, current use of immunosuppressive medication, currently on warfarin or any known bleeding disorder are excluded.

What is involved in this Study? This is an open label trial looking at the effects of Li on muscle strength. Procedures consist of a baseline muscle biopsy, blood work, and other screening procedures. After the muscle biopsy patients are started on Li at 300mg/d. Lithium doses are dependent on tolerability and target lithium levels. Monthly visits consist of EKGs, Li level labs, questionnaires, and muscle strength testing. At month 6, patients will receive another muscle biopsy. The muscle biopsies are performed to analyze p-tau levels in the muscle.

How long is the Study? It is approximately 6 months long; however patients have the option to stay on the study for an additional 6 months.

Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Muscle Biopsies will be taken at baseline and at the end of 6 months. Tissue will be frozen then sent out for anaylsis.
Probability Sample
Patients who fit criteria diagnosed with IBM
Inclusion Body Myositis
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
December 2009
November 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age >30
  • Meet diagnostic criteria for definite IBM
  • Muscle function adequate for quantitative muscle testing
  • Able to give informed consent
  • Women of child bearing potential must have a negative pregnancy test

Exclusion Criteria:

  • Presence of uncontrolled diabetes, hypothyroidism, chronic infection, chronic renal insufficiency, congestive heart failure, cancer, or other chronic serious medical conditions
  • Significant arrhythmias or conduction defect abnormalities on ECG
  • Pregnant or lactating
  • Coexistence of other neuromuscular or neurological diseases that would interfere with assessment
  • Known bleeding disorder
  • On Warfarin
  • Contraindications to muscle biopsy: allergy to local anesthetic, skin infection, known bleeding disorder
Sexes Eligible for Study: All
30 Years to 88 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
WIRB #: 20071696
Study Number 1093885
Not Provided
Not Provided
David Saperstein, MD, Phoenix Neurological Associates, LTD
Phoenix Neurological Associates, LTD
Not Provided
Principal Investigator: David D Saperstein, MD Phoenix Neurological Associates, LTD
Phoenix Neurological Associates, LTD
February 2010